Diabytes
Sun Pharmaceutical Industries News
)
When he started his pharma company in 1983 with 5 products and 5 people, hardly anyone could guess the success he will achieve. In 1987 when the company began selling on a national scale, it was ranked 108th. Now it ranks 6th, which is nothing short of mind-blowing.
)
The company had posted a net profit of Rs 321.57 crore for the corresponding period of the previous fiscal hit by one-time deferred tax adjustment.
)
In November 2018, a whistleblower approached Sebi with a document alleging various irregularities by the company, its promoter and others.
)
Sun Pharmaceutical Industries on Tuesday reported a consolidated net profit of Rs 982.51 crore for the quarter ended June 30, 2018.
)
The share purchase will be for a cash consideration of MYR 2,861,365.65, Sun Pharma said.
)
On US FDA inspection, Shanghvi said on completion of re- inspection, the USFDA issued nine observations for the Halol facility and the company is currently in the process of implementing the requisite remediation steps.
)
The scrip settled 7.02 per cent higher at Rs 494.95 on the BSE. In the intra-day trade, the stock climbed 8.95 per cent to the day's high of Rs 503.90 on the BSE.
)
The stock plunged 5.13 percent to settle at Rs 474.75 on BSE. During the day, it slumped 5.63 percent to Rs 472.20 -- its 52-week low.
)
Drug major Sun Pharmaceutical Industries on Wednesday said the US health regulator has accepted biologics licence application (BLA) for tildrakizumab for the treatment of psoriasis.
)
Drug major Sun Pharmaceutical Industries has received 11 observations from the US health regulator after inspection of its Dadra facility.
)
As a result of disappointed December-quarter earnings by major players, Indian shares fell on Wednesday, with Tata Motors and Sun Pharmaceutical Industries weighing on the indexes.
)
Pharamceutical major Sun Pharma's subsidiary has invested USD 13 million (about Rs 88 crore) in the US-based scPharmaceuticals Inc, announced the company on Friday.
)
Pharmaceutical major Sun Pharma has informed BSE that it has completed the acquisition of the US-based eye care specialist Ocular Technologies Sarl.
)
The vaccine will be targeted against all the four serotypes of dengue virus that cause fever, headache, muscle and joint pain, rash in humans.
)
Indian drug major Sun Pharmaceutical Industries Ltd said it entered into $50 million licensing agreement with Spanish firm Almirall for the development and commercialisation of tildrakizumab for psoriasis in Europe.
)
New Delhi: Drug major Sun Pharmaceutical Industries on Wednesday announced the launch of its sunscreen brand 'Suncros' through the company's Global Consumer Healthcare business vertical.
)
The company is likely to commercialise BromSite through its newly formed US-based division Sun Ophthalmics in the second half of 2016.
)
Drug major Sun Pharmaceutical Industries has made a tender offer to acquire US-based eyecare firm InSite Vision for USD 0.35 per share in cash.
)
Drug major Sun Pharmaceutical Industries has entered into an agreement with InSite Vision to acquire the US-based eyecare firm for around USD 48 million plus related debt and other transaction costs to strengthen its branded ophthalmic portfolio in the US.
The company has started the integration of opiates business after completion of the deal, which would strengthen its position in global market and expand its narcotics raw material (NRM) market share.
Loading...
 "Will Hindus get justice in Bengal's Murshidabad?")
 "DNA: Uproar over freebies in Delhi!")
 "DNA: AIMIM plans to field 2020 Delhi riots accused Shahrukh Pathan")
 "DNA: A report showing the reality of Bangladesh")
 "DNA: Power Theft Allegations Against SP MP Ziaur Rahman Barq")
 "DNA: Hot Tea Linked to Cancer Risk!")
 "DNA: Why Jordan Fears After Syria’s Coup?")
 "DNA: NSA Ajit Doval’s China Visit - Inside Story")
 "DNA: Gandhi Family Ruined My Career, says Mani Shankar Aiyar")
 "DNA: Ground Report- Tight Security Arrangements for Mahakumbh")
